Urinary tract infections (๋น„๋‡จ๊ธฐ๊ณ„ ๊ฐ์—ผ์ฆ)

1. Introduction

(1) Defense mechanisms of urinary tract

Defense mechanism
Normal urination- Adequate flow
- Complete, frequent voiding (๋ฐฐ๋‡จ) : ์„ธ๊ท  ์ •์ฒด ์—†์ด ์ œ๊ฑฐ
Anatomical structures- Length of urethra
- Urethral high pressure zone : ์š”๋„๊ทผ์œ„๋ถ€ ์ฃผ๋ฆ„ ํŒฝ์ฐฝ์œผ๋กœ ์••๋ ฅ ์ƒ์Šน
- Urethral peristalsis
Antimicrobial urine- High urea content
- Low urine pH : ๊ท  ์„ฑ์žฅ ์–ต์ œ
- Osmolarity
- Organic acids
- Tamm-Horsfall protein
Mucosal defence barrier- Balanced distal urethra microflora
- Surface IgA antibodies
- Glycosaminoglycan layer
- Exfoliation of urothelial cells
  • ์ด๋Ÿฌํ•œ ๋ฐฉ์–ด ์ฒด๊ณ„๊ฐ€ ๊นจ์ง€๋ฉด ๊ฐ์—ผ์— ์ทจ์•ฝํ•ด์ง.

(2) Definition

  • ์™ธ๋ถ€ ํ™˜๊ฒฝ์—์„œ bacteria๊ฐ€ urethra(์š”๋„)๋กœ ๋“ค์–ด๊ฐ€, ์‹ ์ฒด์˜ ๋ฉด์—ญ ๋ฐฉ์–ด ์ฒด๊ณ„๋ฅผ ๊นจ๋œจ๋ฆฌ๊ณ  uniray tract(๋น„๋‡จ๊ธฐ๊ณ„)์— ๊ฐ์—ผ์„ ์œ ๋ฐœํ•œ ์ƒํƒœ.
    (Conditions that happen when bacteria from the external environment enter the urethra, evade the bodyโ€™s immune defenses and cause urinary tract infection)

UPPER urinary tract infection (์š”๊ด€)
Kidney infectionPyelonephritis (์‹ ์šฐ์‹ ์—ผ)
Ureter infection : ๋‹จ๋… ๋ฐœ์ƒ ์ ์ŒUreteritis (์š”๊ด€์—ผ)
LOWER urinary tract infection (์š”๋„)
Bladder infection : ์••๋„์ ์œผ๋กœ ๋งŽ์ŒCystitis (๋ฐฉ๊ด‘์—ผ)
Urethra infection : ๋‹จ๋… ๋ฐœ์ƒ ์ ์ŒUrethritis (์š”๋„์—ผ)

(3) Predisposition, incidence, risk factor

  • ๊ฐœ์—์„œ๋Š” 5-27% ๋กœ ํ”ํ•จ / ๊ณ ์–‘์ด์—์„œ๋Š” <2%
๊ฐœ์—์„œ์˜ predisposition & incidence
Female > Male
2์‚ด ์ดํ•˜๋‚˜ 6์‚ด ์ด์ƒ์—์„œ ๋งŽ์ด ๋ฐœ์ƒ
ํ˜ธ๋ฐœ ํ’ˆ์ข…์€ ๋”ฐ๋กœ ์—†์Œ
DM(Diabetes mellitus) ๋˜๋Š” hyperadrenocorticism ํ™˜์ž์˜ 41.6%์—์„œ
Long-term glucocorticoids ์ ์šฉ ์‹œ 18-39%์—์„œ
๊ณ ์–‘์ด์—์„œ๋Š”..
10์‚ด ์ด์ƒ์—์„œ ๋งŽ์ด ๋ฐœ์ƒ
Risk factor : Persian ํ’ˆ์ข…, females, ๋‚˜์ด๋“ฆ, ์ฒด์ค‘ ๊ฐ์†Œ
ํ˜น์€ ์–ด๋ฆฐ ๋‚˜์ด์—๋„ ์š”๋กœ๊ณ„ ์ž๊ทน์ด ์ง€์†๋˜๋ฉด ๋ฐœ๋ณ‘ ๊ฐ€๋Šฅ (์š”์นดํ…Œํ„ฐ, ์ˆ˜์ˆ  ๋“ฑ)
CKD์˜ 17-30%, DM์˜ 12-13%, Hyperthyroidism์˜ 12-22%์—์„œ

2. ๋ถ„๋ฅ˜

(1) Classification of Bacterial cystitis (์„ธ๊ท ์„ฑ ๋ฐฉ๊ด‘์—ผ์˜ ๋ถ„๋ฅ˜)

  • Uncomplicated UTI = Sporadic bacterial cystitis (์‚ฐ๋ฐœ์„ฑ ์„ธ๊ท ์„ฑ ๋ฐฉ๊ด‘์—ผ) : ๊ฑด๊ฐ•ํ•œ ๊ฐœ์ฒด์—์„œ ์‚ฐ๋ฐœ์ /์ผ์‹œ์ ์œผ๋กœ ๋ฐœ์ƒ
  • Complicated UTI : ์ง€์†์ , ์žฌ๋ฐœ์„ฑ ๊ฐ์—ผ, ์น˜๋ฃŒ ์‹คํŒจ๋กœ ์ด์–ด์งˆ ์ˆ˜ ์žˆ์Œ.
    • Recurrent UTI : 1๋…„ ๋™์•ˆ 3ํšŒ ์ด์ƒ ์žฌ๋ฐœ
      • ==Relapsing (์žฌ๋ฐœ) : ์™„์ „ํžˆ ์น˜๋ฃŒ๋˜์—ˆ๋Š”๋ฐ, ๋˜‘๊ฐ™์€ ๊ฐ์—ผ์ฒด์— ์˜ํ•ด ์žฌ๋ฐœ (๊ฐ์—ผ์›์˜ ์ž”์กด)==
      • Persistent (์ง€์†๊ฐ์—ผ) : ์น˜๋ฃŒํ–ˆ์œผ๋‚˜, ์ง€์†์ ์œผ๋กœ ์„ธ๊ท  ๊ด€์ฐฐ๋จ (์ˆ™์ฃผ ๋ฉด์—ญ ๋ฌธ์ œ, ํ•ญ์ƒ์ œ ๋‚ด์„ฑ๊ท )
      • Reinfection (์žฌ๊ฐ์—ผ) : ์ƒˆ๋กœ์šด ๊ฐ์—ผ์ฒด์— ์˜ํ•ด ์œ ๋ฐœ
      • Refractory : ์น˜๋ฃŒ ๋ฐ˜์‘ ์—†์Œ - ์ฆ์ƒ ๊ฐœ์„  X, ์„ธ๊ท  ์‚ฌ๋ฉธ X
  • Subclinical bacteriuria (asymptomatic bacteriuria) : ์ž„์ƒ์ฆ์ƒ(LUTS, lower urinary tract signs)์€ ์—†์ง€๋งŒ ๊ท  ๊ฒ€์ถœ

Complicated UTI์˜ ์š”์ธ

  • ํ•ด๋ถ€ํ•™์  ์š”์ธ : ectopic ureters(์ด์†Œ์„ฑ ์š”๊ด€), ureteroceles(์š”๊ด€๋ฅ˜)
  • ์ „์‹  ์งˆํ™˜ : DM, hyperthyroidism, HAC(๋ถ€์‹ ํ”ผ์งˆ๊ธฐ๋Šฅํ•ญ์ง„์ฆ), systemic neoplasia, immunocompromised(๋ฉด์—ญ์ €ํ•˜)
  • ๋น„๋‡จ๊ธฐ๊ณ„ ์ž์ฒด ๋ฌธ์ œ : urolithiasis(์š”๋กœ๊ฒฐ์„), cystic neoplasia(๋ฐฉ๊ด‘์ข…์–‘), deep seated bacterial cystitis(์‹ฌ์ธต ์„ธ๊ท ์„ฑ ๋ฐฉ๊ด‘์—ผ)

๐ŸŸก Pyelonephritis (์‹ ์šฐ์‹ ์—ผ)

  • Acute pyelonephritis (APN) : ๋ณดํ†ต ์„ธ๊ท ์ด ํ•˜๋ถ€ ์š”๋กœ์—์„œ ์ฝฉํŒฅ๊น”๋•Œ๊ธฐ(renal pelvis), ์ฝฉํŒฅ ์‹ค์งˆ(parenchyma)๋กœ ์˜ฌ๋ผ๊ฐ€๋ฉด์„œ ๋ฐœ์ƒ. ๋ฉฐ์น ~๋ช‡ ์ฃผ ๋‚ด๋กœ ๋ฐœ๋ณ‘. ๊ฐ€๋” ํ˜ˆํ–‰์„ฑ(hematogenous)์œผ๋กœ๋„ ๋ฐœ์ƒํ•จ.
    • Complicated APN : DM, ์ข…์–‘, ๋ฉด์—ญ์ €ํ•˜, ํ•ด๋ถ€ํ•™์  ๋ฌธ์ œ ๋“ฑ ์ „์‹  ์งˆํ™˜๊ณผ ํ•จ๊ป˜ ๋‚˜ํƒ€๋‚˜๋Š” ๊ฒฝ์šฐ
    • Noncomplicated APN

๐ŸŸก Bacterial prostatitis (์„ธ๊ท ์„ฑ ์ „๋ฆฝ์„ ์—ผ)

  • ์„ฑ์ˆ™ํ•œ ์ˆ˜์ปท ๊ฐœ์—์„œ ์ฃผ๋กœ ๋ฐœ์ƒํ•˜๋ฉฐ, ๋งŒ์„ฑ ๋˜๋Š” ๊ธ‰์„ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚จ.
    • Bacterial cystitis๋„ ํ•จ๊ป˜ ๋™๋ฐ˜ํ•  ๋•Œ๊ฐ€ ๋งŽ์Œ.
    • ์ „๋ฆฝ์„  ๋†์–‘์œผ๋กœ ์ง„ํ–‰๋˜๋ฉด ํŒŒ์—ด๊ณผ ๊ฐ™์€ ์‹ฌ๊ฐํ•œ ์งˆ๋ณ‘์„ ์ดˆ๋ž˜ํ•  ์ˆ˜ ์žˆ์Œ.

DDx for Bacterial prostatitis

  • Prostatic neoplasia (์ „๋ฆฝ์„  ์ข…์–‘)
  • Prostatic cyst (์ „๋ฆฝ์„ฑ ๋‚ญ์ข…)
  • Prostatic hyperplasia (์ „๋ฆฝ์„  ๋น„๋Œ€์ฆ)
  • Perirectal mass (์ง์žฅ์ฃผ์œ„ ์ข…์–‘)
  • Periprostatic mass (์ „๋ฆฝ์„ ์ฃผ์œ„ ์ข…์–‘)
  • Disease causing tenesmus (์ด๊ธ‰ํ›„์ฆ; ํ•ญ๋ฌธ ๋ถˆ์™„์ „ ๋ฐฐ๋ณ€๊ฐ ์œ ๋ฐœ ์งˆํ™˜)
    - e.g) large intestinal disease

3. ์ž„์ƒ์  ํŠน์ง•

  • ๋ฐฉ๊ด‘์—ผ์—์„œ ์ผ๋ฐ˜์ ์ธ ์ฆ์ƒ
    • Typical LUTS (lower urinary tract signs) : stranguria(ํ†ต์ฆ๋ฐฐ๋‡จ), hematuria(ํ˜ˆ๋‡จ), pollakuira(๋นˆ๋‡จ), periuria(์ด์ƒ๋ฐฐ๋‡จ; ๋‹ค๋ฅธ ๊ณณ์— ์†Œ๋ณ€), dysuria(๋ฐฐ๋‡จํ†ต)
    • ์–ด๋ฆฐ ๊ณ ์–‘์ด์˜ ๊ฒฝ์šฐ feline idiopathic cystitis ๋จผ์ € ์˜์‹ฌ
    • Excessive licking (๊ณผ๋„ํ•œ ํ•ฅ์Œ)
  • ๊ธ‰์„ฑ ์‹ ์šฐ์‹ ์—ผ(APN)์—์„œ ์ž˜ ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ
    • ๋ฐœ์—ด, ์‹์š•๋ถ€์ง„, ๊ธฐ๋ ฅ์ €ํ•˜, ๊ตฌํ†  + PUPD(๋‹ค์Œ๋‹ค๋‡จ)
  • ๊ธ‰์„ฑ ์ „๋ฆฝ์„ ์—ผ(acute prostatitis)์—์„œ ์ž˜ ๋‚˜ํƒ€๋‚˜๋Š” ์ฆ์ƒ
    • Purulent/hemorrhagic urethral disharge (ํ™”๋†์„ฑ, ์ถœํ˜ˆ์„ฑ ์š”๋„ ๋ถ„๋น„๋ฌผ)
    • ๋ฐœ์—ด, ์‹์š•๋ถ€์ง„, ๊ธฐ๋ ฅ์ €ํ•˜, ๊ตฌํ†  + preputial edema, hindlimb edema, tenesmus(์ด๊ธ‰ํ›„์ฆ)
  • Abdominal pain(๋ณต๋ถ€ ํ†ต์ฆ)๋„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์Œ

4. ์ง„๋‹จ

๊ธฐ์ค€
Signalment- APN(๊ธ‰์„ฑ์‹ ์šฐ์‹ ์—ผ) : Boxer
- Prostatitis(์ „๋ฆฝ์„ ์—ฝ) : ์„ฑ์ˆ™ ์ˆ˜์ปท, ํ‰๊ท  7-11์„ธ
๋ฌธ์ง„ ์ฒญ์ทจ๊ธฐ์ €์งˆํ™˜ ์œ ๋ฌด, ์žฌ๋ฐœ ์—ฌ๋ถ€ ๋“ฑ
์‹ ์ฒด ๊ฒ€์‚ฌ๋ณต๋ถ€ ์ด‰์ง„, ์ง์žฅ ์ด‰์ง„, ํ”ผ๋ถ€ ๊ฒ€์‚ฌ, digital vaginal ๊ฒ€์‚ฌ (์งˆ, ์™ธ์Œ๋ถ€ ๊ฐ์—ผ ์žˆ๋Š”์ง€)
- cycstitis (๋ฐฉ๊ด‘์—ผ)- ์ž‘๊ณ , ๋นˆ ๋ฐฉ๊ด‘ / ๋ฐฉ๊ด‘๋ฒฝ ๋น„ํ›„ (*๋“œ๋ฌผ๊ฒŒ ๊ฒฐ์„, ์ข…์–‘ ๋“ฑ์œผ๋กœ ๋ฐฉ๊ด‘ ๋น„๋Œ€)
- caudal abdominal or lumpar pain
- APN (๊ธ‰์„ฑ ์‹ ์šฐ์‹ ์—ผ)- flank, abdominal, sublumbar pain
- kidney failure(์‹ ๋ถ€์ „)์œผ๋กœ ๋ฐœ์ „ํ•  ๊ฐ€๋Šฅ์„ฑ
- Prostatitis (์ „๋ฆฝ์„ ์—ผ)- ์ „๋ฆฝ์„ ์˜ ๋น„๋Œ€์นญ ํ™•์žฅ, ๊ณ ํ†ต (*๋“œ๋ฌผ๊ฒŒ ์–‘์ธก์„ฑ, ๋น„๋Œ€๋˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Œ)
- preputial, hindlimb edema
Urinalysis
๋ฌผ๋ฆฌ์  ๊ฒ€์‚ฌ- ํ˜ˆ๋‡จ and/or ๋†๋‡จ
- USG(์š”๋น„์ค‘)์˜ variation์ด ํผ
ํ™”ํ•™์  ๋ถ„์„- Dip-stick์—์„œ ํ˜ˆ๋‡จ, ๋‹จ๋ฐฑ๋‡จ
UPC ratio- ์‹ฌํ•œ ๋‹จ๋ฐฑ๋‡จ๊ฐ€ ํ™•์ธ๋œ ๊ฒฝ์šฐ ์„ ํƒ์ ์œผ๋กœ
์นจ์ „๋ฌผ ๊ฒ€์‚ฌ
(์š”์นจ์‚ฌ ๊ฒ€์‚ฌ)
- ์—ผ์ฆ ์„ธํฌ : >5 WBC/400๋ฐฐ ์‹œ์•ผ
- ์„ธ๊ท  ํ™•์ธ : ์ˆ˜, ๋ชจ์–‘, intra/extracellular, phagocytosis ํ™•์ธ ๋“ฑ
- Wet ๊ฒ€์‚ฌ โ†’ ๊ฒฐ์„, dry์—์„œ ํ™•์ธ๋˜์ง€ ์•Š์€ ์ด์ƒ ์„ธํฌ, RBC ์‚ฐ์žฌ ์ •๋„
Urine culture* ๋ฐฐ์–‘ ์˜๋ขฐ ์ „ 3-5์ผ๊ฐ„ ํ•ญ์ƒ์ œ ์ฒ˜์น˜ ์ค‘๋‹จ
Indications
(๊ถŒ์žฅ๋˜๋Š” ์ƒํ™ฉ)
- ๊ฒฝํ—˜์ (empiric) ์น˜๋ฃŒ๋กœ ๊ฐœ์„ ๋˜์ง€ ์•Š์Œ
- ์žฌ๋ฐœ์„ฑ(recurrent) UTIs
- ๊ธ‰์„ฑ ์‹ ์šฐ์‹ ์—ผ(APN) : Nephropyelocentesis(์‹ ์šฐ์ฒœ์ž), blood culture ๊ณ ๋ ค
- ๊ธ‰์„ฑ ์ „๋ฆฝ์„ ์—ผ : Prostate culture ๊ณ ๋ ค (๋Œ€๋ถ€๋ถ„ ๋ฐฉ๊ด‘์ฒœ์ž์—์„œ ์ฐพ์•„์ง€๊ธด ํ•จ)
Urine sampling & handling
(์†Œ๋ณ€์˜ ์ฑ„์ทจ์™€ ์ทจ๊ธ‰)
- ๊ฐ€์žฅ ์ด์ƒ์ ์ธ ์ฑ„์ทจ : cystocentesis (๋ฐฉ๊ด‘ ์ฒœ์ž)
- ๋“œ๋ฌผ๊ฒŒ urethral catheterization(์นดํ…Œํ„ฐ ์‚ฌ์šฉ)์œผ๋กœ ๋Œ€์ฒด
- ์ด์ƒ์ ์ธ ๋ณด๊ด€ : UTT (urine culture transport tubes) + preservative (๋ณด์กด์ œ)
- 24์‹œ๊ฐ„ ๋‚ด ์‹คํ—˜์‹ค ์ˆ˜์†ก ๊ถŒ์žฅ (๋ณด์กด์ œ ์žˆ์–ด๋„ <48H)
- ๊ธฐ๋ณธ ์š”๊ฒ€์‚ฌ๋Š” ๋ณด์กด์ œ ์—†์ด syringe ๋ณด๊ด€ํ•ด๋„ ๋จ.
Susceptibility testing
(ํ•ญ์ƒ์ œ ๊ฐ์ˆ˜์„ฑ ๊ฒ€์‚ฌ)
- โ€˜ํ˜ˆ์ฒญ ํ•ญ์ƒ์ œ ๋†๋„โ€™๊ฐ€ ๊ธฐ์ค€ (โ€˜์†Œ๋ณ€ ํ•ญ์ƒ์ œ ๋†๋„โ€™์™€๋Š” ์ƒ์ดํ•  ์ˆ˜ ์žˆ์Œ)
- ๋‘ ๊ฐ€์ง€ ์ด์ƒ์ด ๋‚˜์˜ค๋ฉด ๊ฐ ์„ธ๊ท ์— ๋Œ€ํ•œ ํ…Œ์ŠคํŠธ ๋‹ค์‹œ ์‹ค์‹œ
- ์†Œ๋ณ€์œผ๋กœ ์ฃผ๋กœ ๋ฐฐ์„ค๋˜๋Š” ํ•ญ์ƒ์ œ์˜ ๊ฒฝ์šฐ, ๋‚ด์„ฑ์ด ์žˆ๋”๋ผ๋„ ํšจ๊ณผ ์žˆ์„ ์ˆ˜ ์žˆ์Œ
โ†’ ํ•ญ์ƒ์ œ ์•ฝ๋ฌผ์˜ ๋Œ€์‚ฌ ๊ฒฝ๋กœ์— ๋”ฐ๋ผ UTI์— ๋งž๋Š” ํ•ญ์ƒ์ œ๋ฅผ ์‚ฌ์šฉํ•  ์ˆ˜๋„ ์žˆ์Œ
๊ฒฐ๊ณผ ํ•ด์„- Susceptible : ํ•ญ์ƒ์ œ ์น˜๋ฃŒ ๊ฐ€๋Šฅ
- Intermittent : ๊ฐ€๋Šฅํ•  ์ˆ˜๋„ ์žˆ์Œ (๋„“์€ ๋ฒ”์œ„๋กœ๋Š” resistant ํ•ด๋‹น)
- Resistant : ์น˜๋ฃŒ ํšจ๊ณผ ์—†์„ ๊ฒƒ
โ€ป ๋‹จ, ์‹คํ—˜์‹ค ๊ฒ€์‚ฌ(in vitro culture)์™€ ์ž„์ƒ ๊ฒฐ๊ณผ(in vivo efficacy)๋Š” ๋‹ค๋ฅผ ์ˆ˜ ์žˆ์Œ!
Routine laboratory tests
CBC- Leukocytosis (Neutrophilic leukocytosis with a left shift)
- uncomplicated(์›๋ฐœ์„ฑ)์™€ ๋‹ฌ๋ฆฌ, complicated UTI์—์„œ๋Š” ํ˜ˆ์•กํ•™์  ๋ณ€ํ™” ๊ฐ€๋Šฅ์„ฑ
- ๊ธฐ์ €์งˆํ™˜, ํ•ญ์•”์น˜๋ฃŒ, ๋ฉด์—ญ๋ ฅ ์ €ํ•˜ ๋“ฑ์œผ๋กœ ์ธํ•ด
- ๋˜๋Š” ์‹ ์šฐ์‹ ์—ผ/์ „๋ฆฝ์„ ์—ผ์„ ๋™๋ฐ˜ํ•  ๋•Œ, ์ „์‹ ๊ฐ์—ผ์ผ ๋•Œ
Serum biochemical profile- Renal azotemia
- ๋งŒ์„ฑ ์‹ ์šฐ์‹ ์—ผ์€ ์‹ ์žฅ์„ ์†์ƒ์‹œํ‚ด โ†’ azotemia, ๊ณ ์ธ์‚ฐํ˜ˆ์ฆ ๋“ฑ

Imaging (์˜์ƒ ์ง„๋‹จ)

Radiographs _Cystitis
- ์ž‘์€ ํฌ๊ธฐ์˜ ๋ฐฉ๊ด‘
- ๋ฐฉ๊ด‘๋ฒฝ์˜ ๋น„ํ›„(thickening), irregularity
Ultrasonography (Abd) _Cystitis
- ๋ฐฉ๊ด‘๋ฒฝ ๋น„ํ›„, ์šฐ๋‘˜ํˆฌ๋‘˜(โˆต์ข…์–‘, polyp)
- ๋ฐฉ๊ด‘ ๋‚ด๊ฐ•์˜ Echogenic sediment


+ Cystocopy(๋ฐฉ๊ด‘๋‚ด์‹œ๊ฒฝ) : ์š”๋„ โ†’ ๋ฐฉ๊ด‘ ๋‚ด๋ถ€
๊ฐ์—ผ ํ™•๋ฅ  ์กด์žฌ
Emphysematous cystitis
(๊ธฐ์ข…์„ฑ ๋ฐฉ๊ด‘์—ผ)
- Complicatted UTI, ๋‹น๋‡จ ํ™˜์ž์—์„œ ์ข…์ข… ๋ฐœ๋ณ‘
- gas-producing bacteria๊ฐ€ ๋ฐฉ๊ด‘ ๋ฒฝ&๋‚ด๊ฐ•์— gas accumulation
- E. coli, Clostridium ๋“ฑ
- DM ํ™˜์ž์—์„œ 33, ์‹ ๊ฒฝ ์งˆํ™˜ ํ™˜์ž์—์„œ 26%, ๋ถ€์‹  ์งˆํ™˜ ํ™˜์ž์—์„œ 19% ๋ฐœ์ƒ
Contrast radiography _Pyelonephritis(contrast = ์กฐ์˜์ œ ์‚ฌ์šฉ)
- Mild to moderate pyelectasia (์‹ ์šฐํ™•์žฅ)
- Distortion of renal pelvis (์‹ ์šฐ ๋ณ€ํ˜•)
Ultrasonography (Abd)_Pyelonephritis
- ๋Œ€ํ‘œ์ ์œผ๋กœ ์ผ์‹œ์ ์ธ ์ฝฉํŒฅ ๋น„๋Œ€ (renal pelvic dilation)
- Ureteral dilation (์š”๊ด€ ํ™•์žฅ)
- Blunting of the renal papilla (์ฝฉํŒฅ์œ ๋‘์˜ ๋‘”ํ™”)
- Echogenic debris (๋‚ด๋ถ€์— ๊ณ ์—์ฝ”์„ฑ ์ž”ํ•ด)

* ์‹ ์šฐ์‹ ์—ผ์ธ๋ฐ ์ฝฉํŒฅ์ด ์ถ•์†Œ๋˜์–ด ์žˆ์œผ๋ฉด, CKD๋‚˜ ๋งŒ์„ฑ ์‹ ์šฐ์‹ ์—ผ์„ ์˜์‹ฌํ•ด๋ณด์ž.

+ Bacterial culture : pyelocentesis(์‹ ์šฐ์ฒœ์ž)๋Š” ์‹ค์งˆ์„ ๊ฑด๋“œ๋ฆด ์ˆ˜ ์žˆ์œผ๋‹ˆ, ๋ฐฉ๊ด‘ sampling๋ถ€ํ„ฐ ์‹œ๋„
Contrast radiographs _Prostatitis
- ์ „๋ฆฝ์„  ๋น„๋Œ€
- ๋†์–‘
- ๋ฐฐ๋‡จ๊ณค๋ž€
Ultrasonography (Abd)_Prostatitis
- ์ „๋ฆฝ์„ ์˜ ๋น„๋Œ€์™€ mildํ•œ hyperechogenecity๋ถ€ํ„ฐ,
- ์‹ฌ๊ฐํ•œ ๋น„๋Œ€์™€ mottled hyperechoic~hypoechoic pattern (์–ผ๋ฃฉ๋œ๋ฃฉํ•œ ํŒจํ„ด) ๊นŒ์ง€ ๋‹ค์–‘ํ•จ.
- mottled sign โ†’ ๊ฐ์—ผ, ์ข…์–‘ ์žˆ์„ ๋•Œ

5. ์น˜๋ฃŒ

  • ๋ฐฉ๊ด‘ ์ข…์–‘, ํ˜ธ๋ฅด๋ชฌ ์งˆํ™˜ ๋“ฑ ๊ธฐ์ €์งˆํ™˜์„ ๋ฐฐ์ œํ•˜๊ณ  ์‹œ์ž‘. (ํ˜น์€ ๊ฐ™์ด ๊ด€๋ฆฌ)
  • ์Šคํ…Œ๋กœ์ด๋“œ/๋ฉด์—ญ์–ต์ œ ์•ฝ๋ฌผ์„ ์‚ฌ์šฉํ•˜๋Š” ํ™˜์ž์—์„œ, ๋น„๋‡จ๊ธฐ๊ณ„์™€ ํ”ผ๋ถ€ ๊ฐ์—ผ์— ์ทจ์•ฝ.
  • ํ•ญ์ƒ์ œ ๊ฐ์ˆ˜์„ฑ ๊ฒ€์‚ฌ ํ›„์— ์ฒ˜๋ฐฉํ•˜๋Š” ๊ฒƒ์ด ๋ฐ”๋žŒ์ง.
  • ์ดˆ๊ธฐ์—๋Š” ํ•ญ์ƒ์ œ๋ณด๋‹ค ์ง„ํ†ต์ œ ์ฒ˜๋ฐฉ ๊ถŒ์žฅ
    • e.g. NSAIDs - ๋‹จ ์‹ ๋…์„ฑ ์กด์žฌ, ์œ ์˜ํ•ด์„œ ์ฒ˜๋ฐฉ.

โœ… Subclinical bacteriuria

  • ์ž„์ƒ ์ฆ์ƒ์€ ์—†์ง€๋งŒ ๊ท ์ด ๋ฐฉ์ถœ๋จ. ์•„๋ž˜์™€ ๊ฐ™์€ ๊ฒฝ์šฐ ์ž˜ ๋‚˜ํƒ€๋‚จ.
    • ๊ธฐ์ € ์งˆํ™˜์ด ์žˆ๋Š” ๊ฒฝ์šฐ - ๋‚ด๋ถ„๋น„ ์งˆํ™˜, ์‹ ์žฅ ์งˆํ™˜, ๋ฐฐ๋‡จ ์žฅ์• (micturition disorders) ๋“ฑ
    • gluticorticoids, immunosuppressive ์•ฝ๋ฌผ ๋ณต์šฉ ์‹œ
    • ํšŒ์Œ๋ถ€ ์š”๋„ ์ ˆ๊ฐœ์ˆ (perineal urethrostomies) ์‹ค์‹œ โ†’ ์š”๋„ ์งง์•„์ ธ ๊ฐ์—ผ๋ฅ  ๋†’์•„์ง.
  • ๋ถˆํ•„์š”ํ•œ ํ•ญ์ƒ์ œ ์ฒ˜๋ฐฉ๋ณด๋‹ค๋Š”, ๋ชจ๋‹ˆํ„ฐ๋ง์ด ๊ถŒ์žฅ๋จ.

โœ… Uncomplicate UTI

  • ISCAID ๊ฐ€์ด๋“œ๋ผ์ธ : 5-7์ผ ํ•ญ์ƒ์ œ ์น˜๋ฃŒ
  • ์ ํ•ฉํ•œ ํ•ญ์ƒ์ œ๋ฅผ ์ฒ˜๋ฐฉํ•˜๋ฉด ์ดํ‹€ ์•ˆ์— ์ฆ์ƒ์ด ๊ฐœ์„ ๋จ.
    • ์†Œ๋ณ€ ๋‚ด์—์„œ์˜ ์„ธ๊ท  ๊ฐœ์„ ๋„ 3-5์ผ ๋‚ด์— ์ด๋ฃจ์–ด์ง.
    • ์ด ๊ฐœ์„ ์ด ๋ณด์ด์ง€ ์•Š์œผ๋ฉด complicate UTI๊ฑฐ๋‚˜, ํ•ญ์ƒ์ œ๋ฅผ ์ž˜๋ชป ์ผ๊ฑฐ๋‚˜.
  • ๋ฐฉ๊ด‘์—ผ ํ™˜์ž์—์„œ ํ•˜๋ฃจ 1๋ฒˆ ์•ฝ์„ ๋จน์ด๋Š” ๊ฒฝ์šฐ, ์ €๋…์— ๋จน์ด๋Š” ๊ฒƒ์„ ๊ถŒ์žฅํ•จ. (์ˆ˜๋ฉด ์‹œ๊ฐ„ ๋™์•ˆ ์ถฉ๋ถ„ํžˆ ์•ฝ๋ฌผ ์ž‘์šฉํ•  ์ˆ˜ ์žˆ๋„๋ก)
  • ๊ฒฝํ—˜์  ํ•ญ์ƒ์ œ๋ฅผ ์šฐ์„  ์ฒ˜๋ฐฉํ•ด์•ผ ํ•˜๋Š” ์ƒํ™ฉ๋„ ์žˆ์Œ. (ํ•ญ์ƒ์ œ ๋‚ด์„ฑ ๊ฒ€์‚ฌ๋ฅผ ๊ฑฐ๋ถ€ํ•  ๋•Œ)
  • Cytology โ†’ ๊ฐ„๊ท , ๋‹จ๊ฐ„๊ท ์ด ๋‹ค์ˆ˜ ๊ด€์ฐฐ๋œ๋‹ค
Cytology
Gram (-)
๊ฐ„๊ท (rod),
๋‹จ๊ฐ„๊ท (bacillus)
Cephalosporins
์šฐ์„ ์ ์œผ๋กœ ๊ณ ๋ ค
==E. coli, Enterobacter,
Klebsiella, Proteus==, etc.
Gram (+)
๊ตฌ๊ท (cocci)
Amoxicillin, Cephalospotin
์šฐ์„ ์ ์œผ๋กœ ๊ณ ๋ ค
Staphylococcus, Streptococcus,
Enterococcus, etc.
์•ฝ๋ฌผ ์ฒ˜๋ฐฉ
Amoxicillin
(11-15mg/kg PO TID)
- ์ž˜ ์‚ฌ์šฉํ•˜๋Š” ์•ฝ๋ฌผ
Trimethoprim-sulfamethoxazole
(15mg/kg PO BID)
Amoxicillin clavulanate
(12.5-25mg/kg PO BID-TID)
Cephalexin
(15-30mg/kg PO BID)
- ์—ฌ๊ธฐ๊นŒ์ง€ 4๊ฐœ์˜ ์•ฝ๋“ค์€ Time-dependent.
Enrofloxacin
(5-20mg/kg PO SID dogs,
5mg/kg PO SID cats)
์‹œ๊ฐ„๋ณด๋‹ค๋Š” Dose-dependent, ํ•˜๋ฃจ 1๋ฒˆ ๋ณต์šฉ.
- ๊ณ ์–‘์ด์—์„œ๋Š” ๋…์„ฑ์ด ์žˆ์–ด ๊ณ ๋†๋„ ์‚ฌ์šฉ X
- ์นจํˆฌ๋ ฅ์ด ๋›ฐ์–ด๋‚จ โ†’ ์žฌ๋ฐœ์„ฑ ๋ฐฉ๊ด‘์—ผ์—์„œ ํ€ด๋†€๋ก ์ œ ์ถ”์ฒœ.
๋‹จ ๋‚ด์„ฑ์ด ์ž˜ ์ƒ๊ธฐ๋‹ˆ, ๊ผญ ํ•„์š”ํ•  ๋•Œ๋งŒ.

โœ… Recurrent & Complicated Bacterial cystitis (์žฌ๋ฐœ์„ฑ ๋ฐฉ๊ด‘์—ผ)

  • ๊ธฐ์ € ์งˆํ™˜ ํ™•์ธ์ด ๊ฐ€์žฅ ์ค‘์š”. 2์ฃผ ์ •๋„ ์ง€์ผœ๋ณด๋ฉฐ ์“ฐ๊ณ , ์น˜๋ฃŒ ๊ธฐ๊ฐ„์€ 4์ฃผ๊นŒ์ง€ ์žก์Œ.
  • ํ€ด๋†€๋ก  ๊ณ„์—ด ์•ฝ๋ฌผ์ด ์กฐ์ง ์นจํˆฌ๊ฐ€ ์ž˜ ๋จ โ†’ ์‹ ์šฐ์‹ ์—ผ, ์ „๋ฆฝ์„ ์—ผ์— ํšจ๊ณผ ์ข‹์Œ. but ๋‚ด์„ฑ ์ฃผ์˜ํ•˜์—ฌ ๋‚จ์šฉํ•˜์ง€ ์•Š๋„๋ก ํ•œ๋‹ค.
  • ์žฌ๋ฐœ์„ฑ โ†’ ์ €ํ•ญ์„ฑ ๊ณ ๋ คํ•˜์—ฌ, monitoring ์‹œ๊ธฐ๋‚˜ ์น˜๋ฃŒ ๋ฐ˜์‘ ๊ธฐ๊ฐ„์„ ๊ธธ๊ฒŒ ๋ณผ ํ•„์š”๊ฐ€ ์žˆ์Œ.
    • ํ•ญ์ƒ์ œ ์น˜๋ฃŒ ์‹œ์ž‘ ํ›„ 7์ผ, ํ•ญ์ƒ์ œ ์น˜๋ฃŒ ์ข…๋ฃŒ ํ›„ 7์ผ, montly basis (3๋ฒˆ ์ •๋„)
  • ํ•ญ์ƒ์ œ๋งŒ์œผ๋กœ ์ž˜ ์•ˆ ๋“ฃ๋Š” ๊ฒฝ์šฐ, ๋ณด์กฐ ์š”๋ฒ•์„ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ์Œ.
    • โ€˜๋ณด์กฐ ์š”๋ฒ•โ€™์ธ ๋งŒํผ, ๋‹จ๋…์œผ๋กœ ์น˜๋ฃŒํ•˜๊ธฐ์—” ์ ์ ˆํ•˜์ง€ ์•Š๋‹ค.

๋ณด์กฐ์ œ: Methenamine

  • Methenamine mandelate, methenamine hippurate
  • cyclic hydrocarbon์œผ๋กœ, ๊ฐ€์ˆ˜๋ถ„ํ•ด๋˜์–ด ammonia์™€ formaldehyde ์ƒ์„ฑ
  • ๋‡จ๋ฅผ ์‚ฐ์„ฑํ™”ํ•˜์—ฌ ์„ธ๊ท  ์ฆ์‹์ด ์–ด๋ ต๊ฒŒ ํ•œ๋‹ค.
  • ๋‹จ, ์†Œ๋ณ€์ด ์‚ฐ์„ฑํ™”๋˜๋ฉด ํ•ญ์ƒ์ œ ํšจ๊ณผ๊ฐ€ ๊ฐ์†Œํ•  ์ˆ˜ ์žˆ๋‹ค
    : Fluoroquinolones, aminoglycoside (gentamycin, amikacin)

๋ณด์กฐ์ œ: Cranberry proanthocyanidins (PACs)

  • ๊ฐœ๋‚˜ ๊ณ ์–‘์ด๊ฐ€ ํฌ๋žœ๋ฒ ๋ฆฌ ๋ง›์„ ์ข‹์•„ํ•˜์ง€ ์•Š์•„, ํŒŒ์šฐ๋” ์ œ์ œ๋กœ ์‚ฌ์šฉ
  • ๋ฐฉ๊ด‘์— ๋Œ€์žฅ๊ท ์ด ๋ถ€์ฐฉํ•˜๋Š” ๊ฒƒ์„ ์–ต์ œํ•˜๋Š” ํšจ๊ณผ๊ฐ€ ์žˆ๋‹ค.

โ“ Treatment failure

์น˜๋ฃŒ ์‹คํŒจ์˜ ์ด์œ 

  • ๋ถ€์ ์ ˆํ•œ ์น˜๋ฃŒ
  • Impaired action of drugs (๋ณดํ˜ธ์ž๊ฐ€ ์•ฝ์„ ์ž˜ ๋จน์ด์ง€ ์•Š์•„์„œ)
    • ์ • ์–ด๋ ค์šฐ๋ฉด 2์ฃผ ์ •๋„ ๊ฐ€๋Š” ์ฃผ์‚ฌ ์ œ์ œ๋กœ ๊ต์ฒด ๋“ฑ
  • ๋‚ด์„ฑ ๊ท ์ฃผ, ๊ธฐ์ € ์งˆํ™˜, ์œ„์žฅ๊ด€ ์งˆํ™˜ ๋“ฑ
  • AMR (antimicrobial resistance) : ํ•ญ์ƒ์ œ ์ €ํ•ญ์„ฑ ์‹ฌ๊ฐ
    • MDR (Multidrug-resistant) bacteria : 3๊ฐœ ์ด์ƒ์˜ ํ•ญ์ƒ์ œ ๊ณ„์—ด์—์„œ ๊ฐ์ˆ˜์„ฑ ์žˆ์Œ. (ํ€ด๋†€๋ก  ์ œ์ œ ๋“ฑ)
    • XDR (Extensively drug-resistant) bacteria : ๊ทธ๋ณด๋‹ค ๋‚ด์„ฑ ํŒจํ„ด์ด ๋” ๊ฐ•ํ•จ. 1-2๊ฐœ ๊ณ„์—ด์—์„œ ๊ฐ์ˆ˜์„ฑ.
    • PDR (Pandrug-resistant) bacteria : ๊ฐ€์žฅ ์‹ฌ๊ฐ, ๊ฑฐ์˜ ๋ชจ๋“  ํ•ญ์ƒ์ œ๊ฐ€ ํšจ๋ŠฅX (๊ทธ๋ž˜๋„ ์‚ฌ๋žŒ์—์„œ๋งŒํผ ๋งŽ์ง€๋Š” ์•Š์Œ)

โœ… Pyelonephritis

  • ์น˜๋ฃŒ ๊ธฐ๊ฐ„์€ 4-6์ฃผ ์ •๋„๋กœ ์žก์Œ.
  • ์กฐ์ง ์นจํˆฌ๋ ฅ์ด ์ข‹์€ ํ•ญ์ƒ์ œ ์‚ฌ์šฉ
    • Fluoroquinolones : enrofloxacin, marbofloxacin, ciprofloxacin) - ๋‚ด์„ฑ ์ฃผ์˜
    • ๊ทธ ์™ธ.. trimethoprim-sulfamethoxazole, amoxicillin, cefovecin ๋“ฑ
  • ์ˆ˜์•ก ์กฐ์น˜๊ฐ€ ์น˜๋ฃŒ์— ์ข‹์Œ (์ด๋‡จ๋ฅผ ๋„์™€์ฃผ๋Š” ๊ฒƒ)
  • ์†Œ๋ณ€ ์ฑ„์ทจ๋ฅผ ํ†ตํ•œ ๋ชจ๋‹ˆํ„ฐ๋ง ํ•„์š” (์น˜๋ฃŒ ์‹œ์ž‘ ํ›„ 14์ผ์งธ, ์น˜๋ฃŒ ์ข…๋ฃŒ ํ›„ 7-14์ผ, ์ดํ›„ ๋‹ฌ๋งˆ๋‹ค 3๋ฒˆ)

โœ… Bacterial prostatitis

  • ์น˜๋ฃŒ ๊ธฐ๊ฐ„์€ ์ตœ์†Œ 4์ฃผ.
  • ํ•ญ์ƒ์ œ ์‚ฌ์šฉ: ์‹ ์šฐ์‹ ์—ผ๋ณด๋‹ค ์ข€ ๋” ์กฐ์ง ์นจํˆฌ ์ž˜ ๋˜๋Š” ์•ฝ๋ฌผ์ด ์š”๊ตฌ๋จ.
    • ์กฐ์ง ์นจํˆฌ๋ ฅ ์ข‹๊ณ , ๋‹จ๋ฐฑ์งˆ ๊ฒฐํ•ฉ ์ ๊ฒŒ ๋˜๊ณ , ์ด์˜จํ™” ์ž˜ ๋˜๋Š” ์•ฝ๋ฌผ (์•„๋ž˜ 3๊ฐ€์ง€๊ฐ€ ๋Œ€ํ‘œ์ )
    • Fluoroquinolones : enrofloxacin (๊ฐ€์žฅ ๋งŽ์ด ์‚ฌ์šฉ) - ์•ˆ ๋˜๋ฉด marbofloxacin
    • Trimethoprim-sulfamethoxazole
    • Chloramphenicol
    • ๊ทธ ์™ธ.. amoxicillin, ampicillin, cephalosporines(cefovecin)
  • ์ ˆ์ œ(์ค‘์„ฑํ™”)๊ฐ€ ๋” ๊ทผ๋ณธ์ ์ธ ์น˜๋ฃŒ
  • ์ „๋ฆฝ์„ ์•ก culture ์‹œ ์‹ค์งˆ์ด ์„ž์—ฌ ์žˆ์„ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ,

6. ์˜ˆํ›„

+ ์˜ˆํ›„ ์ธ์ž- ์˜ˆํ›„ ์ธ์ž
Cystitis- Most uncomplicated UTIs
- ์ ์ ˆํ•œ ์น˜๋ฃŒ โ†’ Highly responsive
- Complicated UTIs
- ๊ธฐ์ € ์›์ธ์„ ์ฐพ๊ฑฐ๋‚˜ ๊ด€๋ฆฌ ์–ด๋ ค์šธ ๋•Œ
Pyelonephritis(์ผ๋ฐ˜์ ์œผ๋กœ ์˜ˆํ›„ ๋‚˜์จ)
Bacterial prostatitis- ํ•ญ์ƒ์ œ ์ž˜ ์“ฐ๋ฉด ์˜ˆํ›„ good
- ์žฌ๋ฐœ ์˜ˆ๋ฐฉ์ด ์ค‘์š”; ์ค‘์„ฑํ™” ๊ถŒ์žฅ

7. ์˜ˆ๋ฐฉ

  • Catheterizaiton ์‹œ ์˜ˆ๋ฐฉ์  ํ•ญ์ƒ์ œ/๊ฐ์—ผ ๋ชจ๋‹ˆํ„ฐ๋ง (์žฌ๋ฐœ์„ฑ UTI ํ™˜์ž์—์„œ๋Š” ์นดํ…Œํ„ฐ ๊ถŒ์žฅX)
  • ์˜ˆ๋ฐฉ์  ํ•ญ์ƒ์ œ ์ฒ˜๋ฐฉ์€ ํšจ๊ณผ๊ฐ€ ๋–จ์–ด์ง€๋Š” ํŽธ
  • ์ €์šฉ๋Ÿ‰ ํ•ญ์ƒ์ œ ๋Š์œผ๋ฉด ๋ฐ”๋กœ ์žฌ๋ฐœ
  • ์œ ์‚ฐ๊ท (probiotics)
  • ๋‹ค๋‹น๋ฅ˜ - D-mannose : ์„ธ๊ท ์˜ ๋ถ€์ฐฉ ์–ต์ œ
  • ๋ณด์กฐ์ œ - Cranberry extract, methenamine
  • ์ค‘์„ฑํ™”(castration) : ์ „๋ฆฝ์„ ์—ผ์˜ ๊ฒฝ์šฐ ๊ณ ๋ ค